Targeting ITGB4/SOX2-Driven Lung Cancer Stem Cells Using Proteasome Inhibitors

CSCs isolated from lung squamous cell carcinoma patients were found to be resistant to cisplatin but knocking down ITGB4 or SOX2 sensitized them to cisplatin. Carfilzomib synergized with cisplatin and suppressed CSC growth by inhibiting ITGB4 and SOX2 expression.